• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

The risk and survival of multiple myeloma as the second primary malignancy in a single Chinese center

by | Jul 11, 2024 | Publications

Transl Cancer Res. 2024 Jun 30;13(6):2905-2912. doi: 10.21037/tcr-23-2336. Epub 2024 Jun 11. ABSTRACT BACKGROUND: As the overall survival (OS) of patients with multiple myeloma (MM) improves, the incidence of second primary malignancy (SPM) in long-term complications...

‘X’ marks the spot! Utilising factor Xa inhibitors to optimise thromboprophylaxis in multiple myeloma

by | Jul 11, 2024 | Publications

Br J Haematol. 2024 Jul 10. doi: 10.1111/bjh.19640. Online ahead of print. ABSTRACT Venous thromboembolism (VTE) remains a significant cause of morbidity and mortality among multiple myeloma patients. Chang and colleagues’ findings indicate that factor Xa...

Metabolomic biomarkers of multiple myeloma: A systemati review

by | Jul 11, 2024 | Publications

Biochim Biophys Acta Rev Cancer. 2024 Jul 8:189151. doi: 10.1016/j.bbcan.2024.189151. Online ahead of print. ABSTRACT Multiple myeloma is an incurable malignancy of clonal plasma cells. Various diagnostic methods are used in parallel to accurately determine stage and...

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

by | Jul 11, 2024 | Publications

Blood Cancer J. 2024 Jul 10;14(1):111. doi: 10.1038/s41408-024-01089-5. ABSTRACT Infection is the leading cause of death in multiple myeloma (MM). However, the cellular composition associated with immune dysfunction is not defined. We analyzed immune profiles in the...

Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation

by | Jul 10, 2024 | Publications

JCO Precis Oncol. 2024 Jul;8:e2300613. doi: 10.1200/PO.23.00613. ABSTRACT PURPOSE: Given the high heterogeneity in survival for patients with multiple myeloma, it would be clinically useful to quantitatively predict the individual survival instead of attributing...

Case Report: Cavernous Sinus Syndrome as the Initial Presentation of Multiple Myeloma

by | Jul 10, 2024 | Publications

Front Ophthalmol (Lausanne). 2022 Mar 30;2:849343. doi: 10.3389/fopht.2022.849343. eCollection 2022. ABSTRACT Multiple myeloma (MM) is the second most common hematologic malignancy and most common primary bone malignancy. Ocular manifestations of MM are extremely rare...
« Older Entries
Next Entries »

Recent Content

  • Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma
  • Subcutaneous Darzalex Faspro Extends PFS in Smoldering Myeloma
  • A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients
  • Subcutaneous Bortezomib Associated With Reduced Incidence of Peripheral Neuropathy in Multiple Myeloma
  • Multiple Myeloma: Key Insights on Diagnosis and Evolving Treatment Strategies
  • Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation
  • Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab
  • Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study
  • The long non-coding RNA CRNDE stabilises SIRT1 protein and influences Hedgehog signalling in multiple myeloma
  • What Does Multiple Myeloma Mean?
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT